E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 3.052 EUR 1.13%
Market Cap: 291.7m EUR

EV/EBITDA
Enterprise Value to EBITDA

4.1
Current
2.4
Median
12.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
4.1
=
Enterprise Value
281.3m EUR
/
EBITDA
68.3m EUR
Market Cap EV/EBITDA
FR
Euroapi SAS
PAR:EAPI
290.6m EUR 4.1
US
Eli Lilly and Co
NYSE:LLY
711.5B USD 34.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
371.5B USD 12.5
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 13.7
CH
Roche Holding AG
SIX:ROG
209.8B CHF 9.5
CH
Novartis AG
SIX:NOVN
186.7B CHF 10.4
UK
AstraZeneca PLC
LSE:AZN
164.9B GBP 131
US
Merck & Co Inc
NYSE:MRK
194.1B USD 8.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
132.7B USD 7.3
EBITDA Growth EV/EBITDA to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBITDA: 394.4
4.1
22%
0.2
US
Eli Lilly and Co
NYSE:LLY
34.5
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
3.9
2-Years Forward
EV/EBITDA
3
3-Years Forward
EV/EBITDA
2.3